Nasdaq halted trading in ACADIA Pharmaceuticals (NASDAQ:ACAD) at 7:00 am ET this morning pending news.
The Ad Comm review of NUPLAZID (pimavanserin) is today.
Update: Ad Comm votes 12 - 2 in favor of approval.
Subscribe for full text news in your inbox
This was corrected on 03/29/2016 at 02:50 PM. Ad Comm backs approval.